Clinical Practice of Multidisciplinary Team-Guided Comprehensive Management for Pediatric Patients with Fabry Disease: A Single-Center Case Series
Authors:
- Yingchao LiuYLYingchao Liu
- Xiaorong LiuXLXiaorong Liu
- Mei YangMYMei Yang
- Quan WangQWQuan Wang
- Wenmiao XuWXWenmiao Xu
- Jiansheng ZengJZJiansheng Zeng
- Tongxin HanTHTongxin Han
- Huawei MaoHMHuawei Mao
- Suyun QianSQSuyun Qian
Open Access
- 1 January 2026
- journal article
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. ume 19, 1-13
Abstract
This study aimed to illustrate the practical application and preliminary outcomes of a multidisciplinary team (MDT) approach in managing pediatric Fabry disease (FD), and provide a reference for the clinical management of this rare disease. This single-center, prospective, observational case series was conducted at Beijing Children’s Hospital. Between March 2021 and February 2024, five pediatric patients with FD who were managed by a dedicated MDT were enrolled. The MDT operated under a model of “identification and initiation in outpatient clinics, overall management by the core team, and specialist consultation as needed.” The workflow covered a dual-path diagnostic pathway (MDT-initiated or external referral), pedigree screening, baseline assessment, individualized treatment, and long-term follow-up. Five pediatric FD probands were enrolled, with four diagnosed through the MDT-initiated pathway and one via external referral. For the four newly diagnosed patients, the MDT achieved a definitive diagnosis within 15–30 days of its engagement, despite a prior diagnostic odyssey of 2.0–5.9 years. Pedigree screening identified an asymptomatic sibling, enabling pre-symptomatic diagnosis. All patients commenced enzyme replacement therapy (ERT, agalsidase α) and did not develop adverse events. Through MDT coordination, they currently maintain continuous ERT at medical institutions with a travel time of 20 minutes to 2 hours. MDT-guided pain treatment, primarily with oxcarbazepine, effectively controlled neuropathic pain in most cases and improved quality of life. Psychosocial support alleviated family burdens, achieving treatment cost reimbursement rates of 60%–85%. At one-year follow-up, symptomatic improvement and significant reductions in globotriaosylsphingosine (Lyso-GL-3) levels were observed. The structured MDT approach facilitated accelerated diagnosis, early intervention, and comprehensive care in this pediatric FD cohort, yielding positive short-term outcomes and providing a practical reference for rare disease management.Keywords
This publication has 34 references indexed in Scilit:
- The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor ProcessDrugs in R&D, 2021
- The benefits and challenges of family genetic testing in rare genetic diseases—lessons from Fabry diseaseMolecular Genetics & Genomic Medicine, 2021
- Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort studyJournal of Inherited Metabolic Disease, 2017
- Treatment of Depression in Adults with Fabry Disease2017
- Fabry disease2015
- Cognitive dysfunction and depression in Fabry disease: a systematic reviewJournal of Inherited Metabolic Disease, 2013
- Correlation between interleukin‐6 promoter and C‐reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry diseaseJournal of Inherited Metabolic Disease, 2008
- Diagnosis of Fabry Disease via Analysis of Family HistoryJournal of Genetic Counseling, 2008
- Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry RegistryJournal of Inherited Metabolic Disease, 2007
- The early clinical phenotype of Fabry disease: a study on 35 European children and adolescentsEuropean Journal of Pediatrics, 2003